Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore-based biologics genetic characterisation test to market

Oxford Nanopore Technologies plc and PathoQuest announce the agreement of a MOU for a collaboration to commercialise a transformational Integration Site Analysis test to better meet the evolving needs of the biopharmaceutical industry and the advancement of biological therapeutics.